NEW YORK – On Opko's conference call to discuss its fourth quarter earnings results, subsidiary BioReference Laboratories emphasized the demand it has seen for rapid point-of-care tests for SARS-CoV-2 as the pandemic rages on.
NEW YORK – On Opko's conference call to discuss its fourth quarter earnings results, subsidiary BioReference Laboratories emphasized the demand it has seen for rapid point-of-care tests for SARS-CoV-2 as the pandemic rages on.
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.